Autologous tumor antigen-presenting dendritic cells (DC vaccine)

Autologous tumor antigen-presenting dendritic cells are a form of personalized cancer immunotherapy where a patient's own dendritic cells are extracted and engineered to trigger an immune response against their tumor. These cells are matured and loaded with tumor-associated antigens or lysates ex vivo, then re-introduced into the patient (Banchereau & Steinman, 1998). Once inside, they migrate to secondary lymphoid organs to present the antigens to naive T cells, effectively teaching the immune system to recognize and attack malignant cells (Anguille et al., 2014). This approach leverages the natural role of dendritic cells as the most potent professional antigen-presenting cells in the body (Palucka & Banchereau, 2012). While the first such therapy, Sipuleucel-T, was approved for prostate cancer, ongoing research explores their use in glioblastoma and melanoma to overcome the immunosuppressive tumor microenvironment (Kantoff et al., 2010).

Other names

Dendritic cell vaccineAutologous DC immunotherapyAntigen-loaded dendritic cellsDC-based cancer vaccineAutologous antigen-presenting dendritic cells

The mechanism involves the ex vivo pulse-loading of autologous dendritic cells with tumor-associated antigens (TAAs), which are then processed and presented on MHC Class I and II molecules. Upon re-infusion, these cells migrate to lymphoid tissues where they provide the signals required for T-cell activation: TCR-MHC binding, co-stimulation (e.g., CD80/86 to CD28), and cytokine secretion (e.g., IL-12), leading to the expansion of tumor-specific effector T cells (Anguille et al., 2014; Palucka & Banchereau, 2012).